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Abstract Orexin A and orexin B (also known as hypocre-
tins) are closely related peptides synthesized by hypotha-
lamic neurons. They orchestrate diverse central and
peripheral processes by stimulation of two G-protein cou-
pled receptors, OX1R and OX2R. Recent studies have dem-
onstrated the ability of orexins to promote a robust apoptosis
in different cancer cells in culture and a potent growth
reduction of human colon tumors in mice xenografts. Here
we report effects of orexins on survival of rat C6 glioma
cells, an experimental model for studies on glioblastoma
multiforme (GBM). Quantitative real-time PCR demonstrat-
ed the expression of both types of orexin receptors in C6
cells. Orexin A and orexin B did not affect rat C6 glioma
cell proliferation as assessed by [3H]thymidine incorpora-
tion assay. Incubation of the cells with orexin A (0.001–
1 μM) resulted in a marked decrease of cell viability. The
observed effect was caspase-dependent, as it was blocked by
Z-VAD-fmk, a pan caspase inhibitor. In addition to that, a
parallel increase in caspase-3 activity was observed. It is
suggested that stimulation of orexin receptors induces death
of rat C6 glioma cells through activation of caspase
pathway.
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Orexins are evolutionarily conserved neuropeptides codis-
covered in 1998 by two independent research groups (de
Lecea et al. 1998; Sakurai et al. 1998). Orexin A (33 amino
acids) and orexin B (28 amino acids) are derived from the
cleavage of a common 130-residue (rodent) or 131-residue
(human) prohormone, prepro-orexin, and share 46 % amino
acid identity in human. Orexin-producing neurons are local-
ized almost exclusively in the dorsal and lateral hypothala-
mus and project to numerous brain structures. Outside the
hypothalamus, orexin-immunoreactive fibers were ob-
served, for example, in the cerebral cortex, olfactory region,
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thalamus, hippocampus, amygdala, locus coeruleus, raphe
nuclei, and area postrema (Nambu et al. 1999). The actions
of orexins are mediated by two membrane bound G-protein
coupled receptors, OX1R and OX2R (Sakurai et al. 1998;
Kukkonen et al. 2002). It has been recently shown that
activated OX1R may exist in a homodimeric form (Xu et
al. 2011). Orexin A is considered as a high-affinity agonist
for OX1R, whereas orexin B has significantly lower affinity
to OX1R. Both peptides show similar affinities to OX2R
(Sakurai et al. 1998; Ammoun et al. 2003).
Accumulating experimental data indicate that orexins con-
trol a number of important physiological processes. They are
best known from their stimulatory effect on feeding behavior,
regulation of energy homeostasis, sleep–wake cycle, reward-
seeking, and drug addiction (Kukkonen et al. 2002; Matsuki
and Sakurai 2008; Aston-Jones et al. 2010; Kodadek and Cai
2010). The peptides also control hypothalamic–pituitary–ad-
renal axis and functions of miscellaneous peripheral organs,
including heart, kidney, pancreas, gastrointestinal tract, thy-
roid, lung, testis, ovaries, and adipose tissue (Voisin et al.
2003; Korczyński et al. 2006; Spinazzi et al. 2006; Heinonen
et al. 2008; Okumura and Nozu 2011; Kagerer and Jöhren
2010). The loss or dysfunction of orexin neurons has been
shown to cause human and animal narcolepsy (e.g., Chemelli
et al. 1999; Lin et al. 1999; Thannickal et al. 2003; Nishino
2007). Recent studies have demonstrated the ability of orexins
to induce apoptosis in cancer cells in culture (Rouet-Benzineb
et al. 2004; Voisin et al. 2011) and to potently reduce the
growth of human colon tumors in mice xenografts (Voisin et
al. 2011). It has been proposed that proapoptotic activity is an
intrinsic property of orexin receptors (El Firar et al. 2009).
In the present work, we investigated the expression of
orexin receptors in rat C6 glioma cells, an experimental model
for studies on glioblastoma multiforme (GBM), and analyzed
effects of orexins on cell survival. Our results show that orexin
A, presumably acting at OX1R, suppresses the growth of C6
cells through activation of caspase pathway.
Materials and Methods
Rat C6 Glioma Cell Cultures
Rat C6 glioma cell line was obtained from the European
Collection of Animal Cell Cultures (Porton Down, UK). The
cells were grown in 60-mm Petri dishes in an F-12 Ham
Nutrient Mixture supplemented with 10 % FBS Gold serum,
2 mM glutamine, 100 U/ml penicillin, and 100 μg/ml
streptomycin in a humidified atmosphere of 95 % air and
5 % CO2 at 37 °C. For subcultures, cells were harvested in
trypsin–EDTA solution twice a week and seeded at a density
of 106 cells per dish. For experimentation, the cells between
passages eight and 20 were used.
Real-Time Quantitative RT-PCR
Total RNAwas extracted from C6 glioma cells by using TRI
Pure Isolation Reagent (Roche, Meylan, France) according
to the manufacturer's instruction. For each sample, total
RNA (1 μg) was subjected to reverse transcription (Rever-
tAid H Minus First Strand cDNA Synthesis Kit; Fermentas,
Burlington, Canada) according to the manufacturer's speci-
fications. Specific sense and antisense oligonucleotide pri-
mers for amplification of mRNAs of rat OX1R and OX2R
were obtained from Invitrogen (Karlsruhe, Germany). The
sequences of specific primers and the procedure of real-time
quantitative PCR (qPCR) were published previously (Jöhren
et al. 2001). Shortly, 2 μl of the first strand cDNA reaction
was incubated in the presence of 3 mM MgCl2; 200 μM of
dGTP, dATP, dCTP, and dUTP; Platinum Taq DNA Poly-
merase; fluorescence dye SYBR green I; and the appropriate
sense and antisense primers in a final volume of 25 μl
(Platinum® SYBR® Green qPCR SuperMix, Invitrogen)
on the 7000 Sequence Detection System of Applied Bio-
systems (Darmstadt, Germany). Each sample was analyzed
in duplicate along with standards and no template controls.
Product purity was regularly confirmed for each sample
by dissociation curve analysis. Copy number calculations
were based on the cycle threshold method (Higuchi et al.
1993). Serial dilutions of known amounts of specific
cDNA fragments were used to generate standard curves.
The threshold cycle number (CT) for each sample was
calculated using the 7000 Sequence Detection System soft-
ware with an automatic baseline setting and a fluorescence
threshold (Rn) of 0.2.
Cell Viability Assay
C6 glioma cells (seeded at a density of 30,000 cells/well) were
grown in 96-well plates in standard culture conditions. Twenty-
four hours before exposing cells to the tested chemicals, the
culture medium was replaced with fresh serum-free medium.
Cell viability and mitochondrial function were measured by
3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bro-
mide (MTT) reduction to MTT formazan by cellular mitochon-
drial dehydrogenases. Following exposure to orexin A and
orexin B for 24 and 48 h, the cell cultures were washed in
PBS before the addition of MTT (0.5 mg/ml) and incubated for
3 h at 37 °C. Formazan crystals were solubilized in dimethyl
sulfoxide (DMSO; 100 %) and absorbance, proportional to the
number of viable cells, was measured at 570 nm using a micro-
plate reader (EnVision 2103, PerkinElmer).
[Methyl-3H]Thymidine Incorporation Assay
Rat C6 glioma cells were seeded on 96-well plates (30,000
cells/well) and cultured in the standard conditions for 24 h to
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allow cell adhesion. The medium was then removed; cells
were washed with PBS, and cultured for another 24 h with
serum-free medium. Thereafter, orexin A and orexin B were
added in serum-free medium, and cells were cultured for 24
or 48 h in the presence 0.5 μCi of [methyl-3H]thymidine
during the last 18 h of incubation. The medium was then
removed, and the cells were washed twice with PBS,
harvested, and solubilized in 0.1 % Tween 20. The
radioactivity of [methyl-3H]thymidine incorporated into
DNA of dividing cells was counted by a β-plate liquid
scintillation counter (MicroBeta TriLux, Luminescence
Counter, PerkinElmer).
In Situ Caspase Activation
Rat C6 glioma cells were seeded at a density of 106 on
poly-L-ornithine (0.01 mg/ml) coated 60-mm Petri
dishes and grown for 24 h in standard culture condi-
tions. The culture medium was then replaced with fresh
serum-free medium, and the cells were cultured for
another 24 h. Thereafter, the medium was replaced with
fresh serum-free medium, containing or not orexins.
After 24 h, caspase activation was detected using the
EnzChek Caspase-3 Assay Kit from Invitrogen Life
Science (Warsaw, Poland) according to the manufac-
turer's information.
Chemicals
Nutrient Mixture F-12 Ham medium, poly-L-ornithine,
DNase I, trypsin, glutamine, penicillin, streptomycin, and
MTT were from Sigma-Aldrich (Poznan, Poland). FBS
Gold was from PAA Laboratories (Cölbe, Germany). dGTP,
dATP, dCTP, and dUTP, and Platinum Taq DNA Poly-
merase were from Invitrogen (Karlsruhe, Germany). Orexin
A and orexin B were from PolyPeptide Laboratories
(Strasbourg, France). Z-VAD-fmk (benzyloxy-carbonyl-
Val-Ala-Asp(OMe)-fluoromethylketone) was purchased
from Tocris Bioscience (Bristol, UK). Petri dishes and
multiwell plates for cell cultures were fromNunc (Wiesbaden,
Germany). [Methyl-3H]thymidine (specific activity
6.7 Ci/mmol) was from PerkinElmer Life Sciences
(Boston, MA, USA). Other chemicals were of analytical
purity and were obtained mainly from Sigma-Aldrich
(Poznań, Poland).
Data Analysis
Data are expressed as mean ± standard error of the mean
(SEM) values and were analyzed for statistical significance
by one-way ANOVA followed by post hoc Student–New-
man–Keul's test using Prism version 5 (GraphPad, San
Diego, CA, USA).
Results
Expression of Orexin Receptors in Rat Glioma C6 Cell Line
Quantitative RT-PCR analysis with specific primers
revealed the presence of both types of orexin receptors in
rat C6 glioma cell line (Fig. 1). The specificity of quantita-
tive RT-PCR was confirmed by subsequent agarose gel
analysis, showing bands specific for OX1R, OX2R, and
GAPDH (data not shown).
Effects of Orexins on Viability of Rat C6 Glioma Cells
To determine effects of orexins on cell survival, C6 glioma
cells were stimulated with various concentrations (0.001–
1 μM) of orexin A and orexin B and examined by MTTassay.
To avoid complex effects from growth factors and other medi-
ators present in serum, the cells were serum-starved for 24 h
prior to exposure to the tested compounds. Rat C6 glioma cells
are viable in serum-free medium, and the mean values of
absorbance units (A572) were only slightly lower compared to
cells cultured in standard conditions (0.35±0.02 versus 0.38±
0.01, n010–12/group, for cells cultured without serum and
cells cultured with serum, respectively). Incubation of rat C6
glioma cells with 0.001–1 μM of orexin A for 24 h decreased
the number of viable cells. The observed effect was
concentration-dependent, with 1 μM of orexin A being the
most potent (decrease by 22 % below the control). The anti-
survival effect of orexin Awas statistically significant in con-
centrations ranging from 0.01 to μM (Fig. 2 top). The
calculated IC50 value for orexin A was 4.7 nM. When the
exposure time had been prolonged from 24 to 48 h, a statisti-
cally significant decrease (by 20 %) in cell viability was seen
only at the highest concentration of orexin A used, i.e., 1 μM
(Fig. 2 bottom). Orexin B showed a tendency to decrease cell
survival, after both 24 and 48 h, but the level of inhibition did
not reach statistical significance (Fig. 2).
Fig. 1 Expression of OX1R and OX2R mRNA in the rat C6 glioma
cell line. Results are expressed as specific mRNA copy numbers per
100 ng of total RNA and represent means ± SEM of eight values per
group
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Orexins Did Not Affect Proliferation of Rat C6 Glioma
Cells
To determine whether the orexin-induced decrease in
cell survival was due to the inhibition of rat C6 glioma
cells proliferation, we evaluated effects of the peptides
on [methyl-3H]thymidine incorporation into the cells.
Both orexin A and orexin B were ineffective in reduc-
tion of the cell proliferation rate (Fig. 3).
Orexin A-Induced Death of Rat C6 Glioma Cells Required
Activation of Caspase Pathway
To test whether activation of caspase pathway is involved in
the orexin A-evoked death of rat C6 glioma cells, caspase-3
activity was measured. The obtained results revealed
concentration-dependent activation of the enzyme (Fig. 4).
The effect of 1 μM orexin A reached the level of statistical
significance, increasing the caspase-3 activity by 67 %
above control. To confirm the importance of caspase-
dependent processes in the studied action of orexin A, a
set of experiments with Z-VAD-fmk, a pan caspase inhibi-
tor, were conducted. This compound, used at a 10 μM
concentration, did not affect the survival of C6 cells. When
Z-VAD-fmk was added to the incubation medium prior to
orexin A (1 μM), it fully blocked the suppressive effect of
the peptide on viability of rat C6 glioma cells as measured
by MTT assay (Fig. 5).
Discussion
The present work demonstrates, for the first time, that orexin
receptors, OX1 and OX2, are expressed at the mRNA level
in the rat C6 glioma cell line. In a search for a potential role
of orexins in C6 glioma cells, we examined effects of the
peptides on their survival. Orexin A suppressed the growth
of the tested cell line. On the contrary, orexin B did not
significantly alter cell viability. Orexin A is considered as a
high-affinity agonist for OX1R, whereas orexin B has a
significantly lower affinity to OX1R. Both peptides show
similar affinities to OX2R (Sakurai et al. 1998; Ammoun et
al. 2003). Thus, it can be hypothesized that activation of
OX1R induces death of rat C6 glioma cells; however, the
involvement of OX2R in the studied action of orexin A
cannot be excluded.
The negligible effect of orexin B (in concentrations up to
1 μM) on survival of C6 glioma cells might reflect ligand
profiling of orexin receptors in these cells, as originally pos-
tulated by Putula et al. (2011). In studies on heterologous cell
lines expressing human orexin receptors, they demonstrated
Fig. 2 Effects of orexin A and orexin B on viability of rat C6 glioma
cells. The cells were incubated with peptides (0.001–1 μM) for 24 h
(top) or 48 h (bottom). The viability of cells was assessed with the aid
of MTT test. The results are expressed as a percent of the respective
control values and represent means ± SEM of nine to 59 values per
group. Asterisk indicates P<0.05, two asterisks indicate P<0.01, three
asterisks indicate P<0.001 versus control
Fig. 3 Effects of orexin A and orexin B on proliferation of rat C6
glioma cells. The cells were incubated with peptides (0.001–1 μM) for
24 h. Proliferative activity of the cells was assessed by [methyl-3H]
thymidine incorporation assay. The results are expressed as a percent of
the mean control value (3,463 cpm) and represent means ± SEM of five
to six values per group
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that the potency of orexinergic agonists (orexin A, orexin B,
and [Ala11,D-Leu15]orexin B) is related not only to the cell
type (receptor expression level, coupling efficiency, and signal
transduction pathways) but also to agonist trafficking of re-
ceptor responses (so-called signal trafficking). In accordance
with our hypothesis are data demonstrating that in human
adrenal cortical cells (expressing almost solely OX1 recep-
tors), orexin A stimulated cortisol secretion with an EC50
value around 0.2 nM, while orexin B was ineffective at con-
centrations up to 1 μM (Mazzocchi et al. 2001). Orexin A, but
not orexin B (also used at 1 μM), concentration dependently
increased corticosterone secretion and enhanced cyclic AMP
production from rat adrenocortical cells (Ziolkowska et al.
2005).
Studies on mechanisms by which orexin A reduced C6
cell survival revealed that the decrease in the number of
cells was not associated with an inhibition of their prolifer-
ation rate, as the peptide did not alter this process. Two lines
of evidence suggest that rat C6 glioma cells' death is asso-
ciated with activation of caspase pathway: (1) orexin A
increased basal caspase-3 activity and (2) incubation of cells
with pan caspase inhibitor suppressed the orexin A-induced
inhibition of cell survival. The antisurvival action of orexins
has been previously demonstrated in experiments conducted
on CHO cells transfected with human OX1R (Ammoun et
al. 2006) and OX2R cDNA (Voisin et al. 2006). Further
studies performed on cell lines derived from human brain
(SK-N-MC) and colon (HT29-D4, Caco-2, SW480, and
LoVo) tumors revealed that the cells die through apoptosis
induction. Notably, although orexins induced apoptosis in
colon cancer cells, the peptides were unable to trigger this
process in normal colonic epithelial cells which, in contrast
to the neoplastic cells, do not express native orexin receptors
(Rouet-Benzineb et al. 2004). Elegant studies performed by
the group of M. Laburthe revealed that the ability to induce
apoptosis is an intrinsic property of orexin receptors (Rouet-
Benzineb et al. 2004; Voisin et al. 2006; Laburthe et al.
2010). They identified two tyrosine-based motifs within the
structure of OX1R, i.e., immunoreceptor tyrosine-based mo-
tif (ITIM) and immunoreceptor tyrosine-based switch motif
(ITSM), and demonstrated that phosphorylation of tyrosines
within these motifs, followed by a recruitment of the tyro-
sine phosphatase SHP-2 and the subsequent activation the
enzyme, are essential steps required for apoptosis driven by
orexins. Downstream events include release of cytochrome
c from mitochondria and activation of caspase-3 and
caspase-7 (El Firar et al 2009; Laburthe et al. 2010).
Although the expression level of orexin receptors in C6
glioma cells was similar to that found in astrocytes from rat
cerebral cortex, orexins had negligible effects on survival of
the latter cell type (Biegańska K, unpublished observation).
Interestingly, orexin A and orexin B, with comparable po-
tencies, suppressed caspase-3 activity and increased viabil-
ity of cultured rat cortical neurons (Sokołowska et al. 2012).
In these cells, the expression level of OX2R is significantly
higher than those observed in rat astrocytes and C6 glioma
cells, a phenomenon that may determine different effects of
orexin B on cell viability in the rat brain (Urbańska et al.
2012). A question arises as to molecular mechanisms un-
derlying dual functions of orexins in the context of cell
growth and survival. Why do the peptides exert antisurvival
activity in one cell type and prosurvival activity in another?
One likely explanation to this might be an intrinsic sensitiv-
ity of cells to the action of cytochrome c. In support of this
Fig. 5 Effects of Z-VAD-fmk (Z-VAD), a pan caspase inhibitor, on
decrease in viability of rat C6 glioma cells induced by 24-h exposure to
orexin A (OX-A). The results are expressed as percent of control values
and represent means ± SEM of 15–43 values per group. Letter a
indicates P<0.001 versus control, letter b indicates P<0.001 versus
orexin A
Fig. 4 Effects of orexin A and orexin B on basal caspase-3 activity in
rat C6 glioma cells. The cells were incubated with the peptides (0.001–
1 μM) for 24 h. The results are expressed as a percent of the respective
control values and represent means ± SEM of five to 13 values per
group. Three asterisks indicate P<0.001 versus control
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hypothesis are data demonstrating that primary neurons
from the mouse cerebellum and cerebral cortex are remark-
ably resistant to cytosolic cytochrome c, whereas tumor
tissue from mouse models of both high-grade astrocytoma
and medulloblastoma display hypersensitivity to cyto-
chrome c when compared with the surrounding brain tissue.
Furthermore, it has been shown that cytosolic cytochrome c
is sufficient to induce apoptosis in various human neoplastic
cell lines: neuroblastoma (SH-SY5Y), glioblastoma
(MGR3, MGR1, D54MG, D247MG, and H392), and me-
dulloblastoma (UW228, D341MED, and MCD1). This dif-
ferential sensitivity to cytochrome c is attributed to high
Apaf-1 levels in the tumor tissue compared with low levels
in the adjacent brain tissue (Johnson et al. 2007). In the
intrinsic pathway of apoptosis, cytochrome c released from
mitochondria, binds to Apaf-1, leading to recruitment of
procaspase-9 and formation of the apoptosome.
Apoptosome-mediated activation of caspase-9 activates
caspase-3 and caspase-7, which promote cell death (Danial
and Korsmeyer 2004). Another possible factor determining
the impact of orexins on cell viability is activation of
mitogen-activated protein kinase (MAPK) signaling path-
ways. Studies performed on human embryonic kidney
(HEK-293) and CHO cells stably expressing human OX1R
and OX2R have demonstrated that orexins can exert oppo-
site effects on cell survival through activation of the classi-
cal MAPK pathways. The ERK1/2 pathway was considered
to be protective, whereas p38 was central for cell death
(Ammoun et al. 2006; Tang et al. 2008). In accordance with
these observation are results of our preliminary experiments
demonstrating that the suppressive action of orexin A on
survival of rat C6 glioma cells was blocked by SB 202190, a
specific p38 MAPK inhibitor, whereas the orexins-induced
increase in viability of cortical neurons was abolished by
U0126, a MEK inhibitor (Biegańska K, Sokołowska P and
Zawilska JB, unpublished data).
Our work was done on rat C6 glioma cell line, a widely
used experimental model for studies on GBM. This cell line is
derived from N,N′-nitromethylurea-induced tumors in
random-bred Wistar–Furth rats (Benda et al. 1968). When
the rat glioma C6 cells are injected into the brain of newborn
rats, they form tumors morphologically similar to GBM (Auer
et al. 1981). GBM is the most common and aggressive type of
malignancy in the central nervous system, and despite the
latest progress in pharmacological and radioactive therapeutic
approaches, it is still resistant to these treatments and generally
considered as an incurable disease (Lim et al. 2011; Cimini
and Ippoliti 2011). A median survival time remains approxi-
mately 15 months for newly diagnosed patients and 7 months
for recurrent/relapsed GBM (Henriksson et al. 2011). Taking
into account the above facts, searching for compounds capable
of inducing glioma cells' death appears of extreme impor-
tance. Along this line, the antisurvival action of orexin A
described in this work, together with the data demonstrating
the ability of orexins to promote a robust apoptosis in different
cancer cells in culture and a potent growth reduction of human
colon tumors in mice xenografts (Rouet-Benzineb et al 2004;
Voisin et al. 2011) points to orexin receptors as new and
promising targets in studies on anticancer therapies.
In conclusion, we provided the first evidence for the
presence of orexin receptors in rat C6 glioma cells. Further-
more, we demonstrated that activation of orexin receptors
by orexin A induces caspase-dependent cell death. The
molecular mechanism(s) by which orexin receptors mediate
C6 cell death, including the intracellular signaling path-
ways, remains to be elucidated.
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